TY - JOUR
T1 - Intralymphatic Immunotherapy
T2 - Update and Unmet Needs
AU - Senti, Gabriela
AU - Freiburghaus, Andreas U.
AU - Larenas-Linnemann, Désirée
AU - Hoffmann, Hans Jürgen
AU - Patterson, Amber M.
AU - Klimek, Ludger
AU - Di Bona, Danilo
AU - Pfaar, Oliver
AU - Ahlbeck, Lars
AU - Akdis, Mübeccel
AU - Weinfeld, Dan
AU - Contreras-Verduzco, Francisco A.
AU - Pedroza-Melendez, Alvaro
AU - Skaarup, Søren H.
AU - Lee, Sang Min
AU - Cardell, Lars Olaf
AU - Schmid, Johannes M.
AU - Westin, Ulla
AU - Dollner, Ralph
AU - Kündig, Thomas M.
PY - 2019
Y1 - 2019
N2 - Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.
AB - Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.
KW - Allergen-specific immunotherapy
KW - Allergy
KW - Clinical trials
KW - Intralymphatic immunotherapy
U2 - 10.1159/000493647
DO - 10.1159/000493647
M3 - Article
C2 - 30391954
AN - SCOPUS:85056460849
VL - 178
SP - 141
EP - 149
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
SN - 1423-0097
IS - 2
ER -